Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, double-blinded, randomized, placebo-controlled, single ascending dose study with food effect crossover and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and hemostatic profile of VE-01902

Trial Profile

A single-center, double-blinded, randomized, placebo-controlled, single ascending dose study with food effect crossover and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and hemostatic profile of VE-01902

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs VE-1902 (Primary)
  • Indications Acute coronary syndromes; Stroke; Venous thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VE-01902-REPLACE-Ia-001
  • Sponsors VCR1
  • Most Recent Events

    • 10 Sep 2018 Planned initiation date changed from 1 Jul 2018 to 15 Oct 2018.
    • 10 Sep 2018 Status changed from planning to not yet recruiting.
    • 15 Jun 2018 According to a Verseon media release, the company will submit an application to the Australian Human Research Ethics Committee to conduct this phase I trial and plans to initiate participant recruitment shortly after receiving approval by the Therapeutic Goods Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top